
Boston Scientific (BSX) Stock Forecast & Price Target
Boston Scientific (BSX) Analyst Ratings
Bulls say
Boston Scientific has demonstrated substantial sales growth across multiple product lines, with Watchman sales increasing by 35% year-over-year, driven by strong adoption in related procedures, and electrophysiology (EP) sales surging by 63%, indicating robust market demand and share gains. The company's guidance for Q4 suggests a positive outlook with expected organic sales growth of 11-13% and projected GAAP EPS between $0.48 and $0.52, reflecting solid operational performance and anticipated revenue generation. Additionally, Boston Scientific's innovations, such as the Nalu device projected to exceed $60 million in sales by 2025 and contribute to a growth rate over 25% in 2026, showcase the firm's effective product pipeline and potential for future profitability in the expanding medical device sector.
Bears say
Boston Scientific is facing a challenging financial landscape, primarily due to expected foreign exchange headwinds, which are projected to negatively impact adjusted earnings by approximately $0.04 per share for the full year. The company is reliant on its cardiac rhythm management (CRM) and drug-eluting stent (DES) portfolios, which operate in mature markets subject to persistent pricing pressures, potentially stifling future revenue growth. Additionally, the firm's ability to meet internal and consensus revenue expectations may be compromised if it struggles with the integration of new acquisitions and experiences delays in launching new products.
This aggregate rating is based on analysts' research of Boston Scientific and is not a guaranteed prediction by Public.com or investment advice.
Boston Scientific (BSX) Analyst Forecast & Price Prediction
Start investing in Boston Scientific (BSX)
Order type
Buy in
Order amount
Est. shares
0 shares